SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Biotechnology Cancer Cures
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (199)11/16/2000 8:00:04 AM
From: Jim Oravetz  Read Replies (2) of 226
 
Nov. 16, 2000--Large Scale Biology Corporation (Nasdaq: LSBC) today announced that it has begun clinical evaluation of its personalized vaccines against B-cell non-Hodgkin's lymphoma (NHL), a type of immune system cancer showing increased incidence and mortality.
LSBC's vaccines are the result of a multi-year collaboration with Dr. Ronald Levy of Stanford University, a pioneer in the field of lymphoma immunotherapy, and are produced in plants using the Company's patented GENEWARE(R) gene expression system.
The Phase I trial will evaluate the safety and preliminary immune response elicited by the vaccines in patients with slowly progressing forms of NHL. Because each patient's tumor displays a different target for vaccine therapy, LSBC's vaccines are "personalized," or patient specific, and are designed to control each patient's disease. Recent studies have demonstrated the effectiveness of patient-specific vaccination, as well as the need for efficient manufacturing approaches to make NHL vaccines commercially viable. LSBC developed GENEWARE(R) technology as a broad platform for the production of pharmaceutical products and is now applying it to the efficient production of NHL vaccines.
Robert L. Erwin, LSBC's CEO stated that, "we expect the clinical trials will demonstrate the effectiveness of our technology platform to make personalized medicine a reality. We are tremendously excited about our NHL vaccines, the success of which will serve as proof of principle for the treatment of cancer and other chronic diseases on an individualized patient basis."

Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News